Table 1.

Adverse reactions occurring >2% in any treatment group from studies evaluating chemotherapy-induced nausea and vomiting^∗

Event	Palonosetron 0.25 mg (N = 633)	Ondansetron 32 mg (N = 410)	Dolasetron 100 mg (N = 194)
Headache	9%	8%	16%
Constipation	5%	2%	6%
Diarrhea	1%	2%	2%
Dizziness	1%	2%	2%
Fatigue	<1%	1%	2%
Abdominal pain	<1%	<1%	2%
Insomnia	<1%	1%	2%

∗Modified with permission from reference 12.